Author

Y. H. Tsang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

A. A. Ivanov· 1 shared A. Wahafu· 1 shared B. J. Druker· 1 shared B. M. Smith· 1 shared C. S. Moreno· 1 shared C. Shu· 1 shared C. Tang· 1 shared D. Cicka· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Ivanov

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

X. Mo, Q. Niu, A. A. Ivanov, Y. H. Tsang, C. Tang, C. Shu, A. Wahafu, S. Doyle, D. Cicka, X. Yang, D. Fan, M. A. Reyna, L. A. D. Cooper, C. S. Moreno, W. Zhou, , H. Fu

The paper identifies mutation-directed neo-protein-protein interactions in cancer using a high-throughput screening platform, revealing therapeutic opportunities through neo-interaction rewiring.

bioRxiv · Oct 3, 2021Cancer Biology

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia

B. M. Smith, J. VanCampen, G. L. Kong, W. Yashar, Y. H. Tsang, W. Horton, D. J. Coleman, J. Estabrook, T. A. Lusardi, G. B. Mills, B. J. Druker, J. E. Maxson, T. P. Braun

This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.

bioRxiv · Aug 24, 2021 · PreprintCancer Biology